(Source: Enanta Pharmaceuticals Inc) Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitors Paritaprevir and ABT-493 at The International Liver Congress™ 2015 Preliminary SVR4 Data of 99 percent Announced on Phase 2b regimens containing ABT-493 and ABT-530 WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 8, 2015-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced today abstracts of research on regimens containing either one of Enanta's two protease inhibitors for hepatitis C virus (HCV) identified and developed in its...
↧